Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease

Journal of Crohn's and Colitis

Volumn 9, Issue 8, 2015, Pages 633-639

  Fiorino, Gionata ^a   Bonifacio, Cristiana ^a   Allocca, Mariangela ^a   Repici, Alessandro ^a   Balzarini, Luca ^a   Malesci, Alberto ^a,b   Peyrin Biroulet, Laurent ^c   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Anti TNF; Bowel damage; Crohn's disease; Inflammatory bowel disease; L mann Index

Indexed keywords

ADALIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CROHN DISEASE; FEMALE; HUMAN; INTESTINE INJURY; LEMANN INDEX; MAJOR SURGERY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ADOLESCENT; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROPORTIONAL HAZARDS MODEL; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973151647     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv080     Document Type: Article

References (33)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011;17: 471-8
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010;105:289-97
3. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a populationbased cohort. Gastroenterology 2010;139:1147-55
4. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota [1970-2004]. Am J Gastroenterol 2012;107:1693-701
5. Fiorino G, Peyrin-Biroulet L, Bonifacio C, et al. MRI and colonoscopy findings in early Crohn's disease predict the course of the disease: a prospective observational cohort study. J Crohn's Colitis 2013;7:S88
6. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5
7. Tavares R, Beattie KA, Bensen WG, et al. A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial. Trials 2014;15:268
8. Higgs JB, et al. Quantitative measurement of erosion growth and joint space loss in rheumatoid arthritis hand radiographs. J Rheumatol 1996;23:265-72
9. Graudal N, Hubeck-Graudal T, Tarp S, et al. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One 2014;9:e106408
10. Pariente B, Cosnes J, Danese S et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22
11. Pariente B, Mary JY, Danese S, et al. Development of the Lemann Index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology 2015;148:52-63
12. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17:1759-68
13. Rimola J, Rodriguez S, García-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009;58:1113-20
14. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. Aliment Pharmacol Ther 2011;34:125-45
15. Ordas I, Rimola J, Rodríguez S, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014;146:374-82 e371
16. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383-95
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
18. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53
19. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis 2011;17:1073-80
20. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514
21. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SESCD. Gastrointest Endosc 2004;60:505-12
22. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001;60:817-27
23. van Der Heijde D, Boonen A, Boers M, et al. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology [Oxford] 1999;38:1213-20
24. Paimela L, Laasonen L, Helve T, et al. Comparison of the original and the modified Larsen methods and the Sharp method in scoring radiographic progression in early rheumatoid arthritis. J Rheumatol 1998;25:1063-66
25. Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6
26. Juhasz P, Mester A, Biró AJ, et al. Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study. BMC Musculoskelet Disord 2014;15:251
27. Ikeda K, Nakagomi D, Sanayama Y, et al. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents. J Rheumatol 2013;40:1967-76
28. Danese S, Peyrin-Biroulet L. IBD: Mucosal healing-EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 2012;9:309-11
29. Oussalah A, Danese S, Peyrin-Biroulet L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review. Curr Drug Targets 2010;11:156-75
30. Panes J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145:766-74
31. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013;145:758-65
32. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95
33. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244-50